natgillin/translations-raw huggingface dataset:
- Patients with chronic wide-angle glaucoma may be treated with Levodopa/Carbidopa/Entacapone Orion with caution, provided the intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra-ocular pressure.
- Patsiente, kellel esineb krooniline avatud nurga glaukoom, tuleb Levodopa/Carbidopa/Entacapone Orion'iga ravida ettevaatlikult ja hoolitseda, et silma siserõhku saaks pidevalt kontrollida ning tekkinud muutused registreeritaks.
HDPE bottle with a child resistant PP-closure.
Kõrgtihedast polüetüleenist pudel lastekindla polüpropüleenkorgiga.
Uncommon (may affect up to 1 in 100 people) - heart attack - bleeding in the gut - changes in the blood cell count which may result in bleeding, abnormal liver function tests - convulsions - feeling agitated - psychotic symptoms - colitis (inflammation of the colon) - discolourations other than urine (e.g. skin, nail, hair, sweat) - swallowing difficulties - inability to urinate
Aeg-ajalt (võib tekkida kuni 1 inimesel 100st): - südame infarkt - verejooks soolestikus - verepildi muutus (mille tulemuseks võib olla verejooks ja maksafunktsioonide testide tulemuste hälve normist) - krambid - erutatus - psühhootilised sümptomid - koliit (jämesoole põletik) - muu kui uriini värvuse muutus (nt nahk, küüned, juuksed-karvad, higi) - neelamisraskused - võimetus urineerida
These include: - dopamine antagonists used to treat mental disorders, nausea and vomiting - phenytoin, used to prevent convulsions - papaverine used to relax the muscles.
Siia hulka kuuluvad: - dopamiini antagonistid, mida kasutatakse vaimse tervise häirete raviks, iivelduse ja oksendamise raviks - fenütoiin, mida kasutatakse krampide ärahoidmiseks - papaveriin, mida kasutatakse lihaste lõõgastamiseks.
b. When initiating Levodopa/Carbidopa/Entacapone Orion therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Levodopa/Carbidopa/Entacapone Orion tablets (50 mg/12.5 mg/200 mg or 75 mg/18.75 mg/200 mg or 100 mg/25 mg/200 mg or 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg), Levodopa/Carbidopa/Entacapone Orion dosing should be carefully titrated for optimal clinical response.
b. Alustades ravi Levodopa/Carbidopa/Entacapone Orion'iga patsientidel, keda parajasti ravitakse entakapooni ning levodopa/karbidopaga annustes, mis ei vasta Levodopa/Carbidopa/Entacapone Orion'i tabletile (50 mg/12,5 mg/200 mg või 75 mg/18,75 mg/200 mg või 100 mg/25 mg/200 mg või 125 mg/31,25 mg/200 mg või 150 mg/37,5 mg/200 mg või 175 mg/43,75 mg/200 mg või 200 mg/50 mg/200 mg), tuleb Levodopa/Carbidopa/Entacapone Orion'i annus ettevaatlikult tiitrida optimaalse kliinilise vastuseni.
If you during the treatment with Levodopa/Carbidopa/Entacapone Orion experience the following symptoms, contact your doctor immediately: - Your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure.
Kui teil esinevad Levodopa/Carbidopa/Entacapone Orion'i kasutamise ajal järgmised sümptomid, pöörduge kohe arsti poole: - Lihased muutuvad väga jäigaks või on koordineerimatud, tekivad krambid, ärevus, segasus, palavik, pulsi kiirenemine või ulatuslik vererõhu kõikumine.
Levodopa/Carbidopa/Entacapone Orion 50 mg/12.5 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 100 mg/25 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 125 mg/31.25 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 150 mg/37.5 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 175 mg/43.75 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg film-coated tablets
Levodopa/Carbidopa/Entacapone Orion 50 mg/12,5 mg/200 mg õhukese polümeerikattega tabletid Levodopa/Carbidopa/Entacapone Orion 75 mg/18,75 mg/200 mg õhukese polümeerikattega tabletid Levodopa/Carbidopa/Entacapone Orion 100 mg/25 mg/200 mg õhukese polümeerikattega tabletid Levodopa/Carbidopa/Entacapone Orion 125 mg/31,25 mg/200 mg õhukese polümeerikattega tabletid Levodopa/Carbidopa/Entacapone Orion 150 mg/37,5 mg/200 mg õhukese polümeerikattega tabletid Levodopa/Carbidopa/Entacapone Orion 175 mg/43,75 mg/200 mg õhukese polümeerikattega tabletid Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg õhukese polümeerikattega tabletid
Patients should be instructed to take only one Levodopa/Carbidopa/Entacapone Orion tablet per dose administration.
Patsiente tuleb juhendada, et nad võtaksid korraga ainult ühe tableti Levodopa/Carbidopa/Entacapone Orion'i.
No particular studies on the pharmacokinetics of carbidopa and levodopa in patients with hepatic impairment are reported, however, it is advised that Levodopa/Carbidopa/Entacapone Orion should be administered cautiously to patients with mild or moderate hepatic impairment.
Teatatud ei ole ühestki põhjalikust karbidopa ja levodopa farmakokineetilisest uuringust maksakahjustusega patsientidel, kuid siiski on soovitatav ravida Levodopa/Carbidopa/Entacapone Orion'iga ettevaatlikult maksapuudulikkusega patsiente, kellel maksakahjustuse aste ulatub kergest keskmise raskusastmeni.
Label 10 tablets 30 tablets 100 tablets 130 tablets 175 tablets
10 tabletti 30 tabletti 100 tabletti 130 tabletti 175 tabletti
Other medicines and Levodopa/Carbidopa/Entacapone Orion
Muud ravimid ja Levodopa/Carbidopa/Entacapone Orion
Therefore, the use of Levodopa/Carbidopa/Entacapone Orion in children or adolescents is not recommended.
Seetõttu pole soovitatav Levodopa/Carbidopa/Entacapone Orion'i lastel või noorukitel kasutada.
Film-coating of 50/12.5/200 mg, 100/25/200 mg and 150/37.5/200 mg: Glycerol (85 per cent) (E422)
Tableti kate 50/12,5/200 mg, 100/25/200 mg ja 150/37,5/200 mg: Glütserool (85 protsenti) (E422)
Elderly: No dose adjustment of Levodopa/Carbidopa/Entacapone Orion is required for elderly.
Eakad: Levodopa/Carbidopa/Entacapone Orion'i annuse vähendamine eakatel ei ole vajalik
Experience with Levodopa/Carbidopa/Entacapone Orion in patients under 18 years is limited.
Levodopa/Carbidopa/Entacapone Orion'i kasutamise kohta alla 18-aastastel lastel on andmeid ebapiisavalt.
ECG monitoring should be started and the patient carefully monitored for the possible development of arrhythmias.
Alustada tuleb ka patsiendi EKG monitooringuga, sest võimalik on arütmiate teke.
Sucrose
Hrvatska
Pack sizes of 75/18.75/200 mg, 125/31.25/200 mg, 175/43.75/200 mg and 200/50/200 mg: 10, 30, 100, 130 and 175 tablets.
Pakendi suurused 75/18,75/200 mg, 125/31,25/200 mg, 175/43,75/200 mg ja 200/50/200 mg: 10, 30, 100, 130 või 175 tabletti.
The daily dose should be preferably optimised using one of the seven available tablet strengths (50 mg/12.5 mg/200 mg, 75 mg/18.75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg, 150 mg/37.5 mg/200 mg, 175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg levodopa/carbidopa/entacapone).
Soovitatavalt peaks päevane annus olema optimeeritud, kasutades ühte seitsmest erineva toimeaine sisaldusega tabletist (vastavalt levodopa/karbidopa/entakapooni sisaldus 50 mg/12,5 mg/200 mg, 75 mg/18,75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31,25 mg/200 mg, 150 mg/37,5 mg/200 mg, 175 mg/43,75 mg/200 mg või 200 mg/50 mg/200 mg).
Hepatic impairment: The metabolism of entacapone is slowed in patients with mild to moderate hepatic impairment (Child-Pugh Class A and B) leading to an increased plasma concentration of entacapone both in the absorption and elimination phases (see sections 4.2 and 4.3).
Maksakahjustus: Entakapooni metabolism on aeglustunud patsientidel, kellel on maksakahjustus kergest mõõduka astmeni (Child-Pugh klass A ja B).
Diarrhoea*, nausea*
Kõhulahtisus*, iiveldus*
Label 10 tablets 30 tablets 100 tablets 130 tablets 175 tablets 250 tablets
10 tabletti 30 tabletti 100 tabletti 130 tabletti 175 tabletti 250 tabletti
Levodopa/Carbidopa/Entacapone Orion comes in six different pack sizes (10, 30, 100, 130, 175 or 250 tablets).
Levodopa/Carbidopa/Entacapone Orion on saadaval kuues erinevas pakendi suuruses (10, 30, 100, 130, 175 või 250 tabletti).
What Levodopa/Carbidopa/Entacapone Orion is and what it is used for
Mis ravim on Levodopa/Carbidopa/Entacapone Orion ja milleks seda kasutatakse
Some patients experience severe abnormal involuntary movements (dyskinesias), mood swings or other side effects after taking large doses of Levodopa/Carbidopa/Entacapone Orion.
Mõnedel patsientidel esineb pärast Levodopa/Carbidopa/Entacapone Orion'i suurte annuste võtmist raskekujulisi tahtele allumatuid ebanormaalseid kehaliigutusi (düskineesiad), meeleolumuutusi või teisi kõrvaltoimeid.
Red iron oxide (E172) Sucrose
Punane raudoksiid (E172) Sahharoos
Serious hepatitis with mainly cholestatic features, rhabdomyolysis and neuroleptic malignant syndrome may occur with Levodopa/Carbidopa/Entacapone Orion although no cases have been identified from the clinical trial data.
Levodopa/Carbidopa/Entacapone Orion ravi puhul võib esineda ka raskeid, peamiselt kolestaasitunnustega maksahäireid, rabdomüolüüsi ja maliigset neuroleptilist sündroomi, kuigi kliinilistes uuringutes ei ole esinenud ühtegi sellist juhtumit.
Therefore Levodopa/Carbidopa/Entacapone Orion should be given cautiously to patients who are taking other medicinal products which may cause orthostatic hypotension.
- Levodopa/Carbidopa/Entacapone Orion võib põhjustada ortostaatilist hüpotensiooni, mistõttu ravimit tuleks annustada ettevaatlikult patsientidele, kes tarvitavad teisi ortostaatilist vererõhu langust põhjustada võivaid preparaate.
Film-coating of 75/18.75/200 mg, 125/31.25/200 mg, 175/43.75/200 mg and 200/50/200 mg: Glycerol (85 per cent) (E422)
Tableti kate 75/18,75/200 mg, 125/31,25/200 mg, 175/43,75/200 mg ja 200/50/200 mg: Glütserool (85 protsenti) (E422)
even if their symptoms signs of illness are the same as yours.
Ravim võib olla neile kahjulik, isegi kui haigusnähud on sarnased.
BOTTLE LABEL AND OUTER CARTON TEXT
PUDELI JA VÄLISPAKENDI MÄRGISTUS
- are allergic to levodopa, carbidopa or entacapone, or any of the other ingredients of this medicine (listed in section 6) - have narrow-angle glaucoma (an eye disorder) - have a tumour of the adrenal gland - are taking certain medicines for treating depression (combinations of selective MAO-A and
6) suhtes allergiline - teil on diagnoositud suletudnurga glaukoom (silmahaigus) - teil on diagnoositud neerupealise kasvaja - te võtate depressiooni ravimiseks teatud ravimeid (selektiivsed MAO-A inhibiitorid koos MAO
- Levodopa/Carbidopa/Entacapone Orion contains sucrose, and therefore patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucraseisomaltase insufficiency should not take this medicine.
Harvaesineva päriliku fruktoositalumatuse, glükoosi-galaktoosi malabsorptsiooni või sahharaasi-isomaltaasi puudulikkusega patsiendid ei tohi seda ravimit kasutada.
What you need to know before you take Levodopa/Carbidopa/Entacapone Orion
Mida on vaja teada enne Levodopa/Carbidopa/Entacapone Orion'i võtmist
Do not take Levodopa/Carbidopa/Entacapone Orion if you:
Ärge võtke Levodopa/Carbidopa/Entacapone Orion'i kui
Eye disorders Common:
Silma kahjustused Sage:
Absorption/distribution: There are substantial inter- and intra-individual variations in the absorption of levodopa, carbidopa and entacapone.
Imendumine/jaotumine: Levodopa, karbidopa ja entakapooni imendumise osas on isikutevahelised jasisesed variatsioonid märkimisväärsed.
The early diagnosis is important for the appropriate management of NMS.
Maliigse neuroleptilise sündroomi ravis on oluline varajane diagnoos.
Biotransformation and elimination: Levodopa is extensively metabolised to various metabolites: decarboxylation by dopa decarboxylase (DDC) and O-methylation by catechol-O-methyltransferase (COMT) being the most important pathways.
Kõige olulisemateks metabolismiteedeks on dekarboksüleerimine dopadekarboksülaasi (DDC) poolt ja O-metüülimine katehhool-O-metüültransferaasi (COMT) poolt.
Chromaturia*
Rabdomüolüüs*
Gastrointestinal haemorrhage
Naatriumkroskarmelloos Magneesiumstearaat Maisitärklis
What Levodopa/Carbidopa/Entacapone Orion looks like and contents of the pack
Kuidas Levodopa/Carbidopa/Entacapone Orion välja näeb ja pakendi sisu
Posology
Kusepeetus
Urinary retention
Trombotsütopeenia
Hepatic impairment: It is advised that Levodopa/Carbidopa/Entacapone Orion should be administered cautiously to patients with mild to moderate hepatic impairment.
Maksakahjustus: Levodopa/Carbidopa/Entacapone Orion'i on soovitav manustada ettevaatusega patsientidele, kellel on leitud maksatalitluse häireid kergest kuni keskmise astmeni.
time with and without entacapone was recorded in home-diaries by patients.
Igapäevaselt mõõdeti patsientide kodustest päevikutest ON-aega entakapooniga ja entakapoonita.
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Levodopa/Carbidopa/Entacapone Orion.
Patsiendid ja hooldajad peavad olema teadlikud sellest, et dopamiini agonistide ja/või teiste levodopat sisaldavate dopamiinergiliste ravimite (nt Levodopa/Carbidopa/Entacapone Orion) kasutamisel võivad tekkida impulsikontrolli häirete käitumuslikud sümptomid, sh patoloogiline hasartmängurlus,
Excipient with known effect: Each tablet contains 1.89 mg of sucrose.
Teadaolevat toimet omavad abiained: Iga tablett sisaldab 1,89 mg sahharoosi.
What Levodopa/Carbidopa/Entacapone Orion contains
Mida Levodopa/Carbidopa/Entacapone Orion sisaldab
Consult your doctor if during the treatment with Levodopa/Carbidopa/Entacapone Orion you: - notice that your muscles get very rigid or jerk violently, or if you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure.
Konsulteerige oma arstiga, kui Levodopa/Carbidopa/Entacapone Orion ravi ajal: - te märkate oma lihaste kangestumist või koordineerimatust või tekivad krambid, meeleolu muutused, segasusetunne, palavik, pulsi kiirenemine või suured muutused vererõhuväärtustes.
75 mg/18.75 mg/200 mg Each tablet contains 75 mg of levodopa, 18.75 mg of carbidopa and 200 mg of entacapone.
75 mg/18,75 mg/200 mg Iga tablett sisaldab 75 mg levodopat, 18,75 mg karbidopat ja 200 mg entakapooni.
125 mg/31.25 mg/200 mg Each tablet contains 125 mg of levodopa, 31.25 mg of carbidopa and 200 mg of entacapone.
125 mg/31,25 mg/200 mg Iga tablett sisaldab 125 mg levodopat, 31,25 mg karbidopat ja 200 mg entakapooni.
Hepatic function test abnormal*
Maksafunktsiooni analüüside tulemuste hälve normist*
If you take more Levodopa/Carbidopa/Entacapone Orion than you should
Kui te võtate Levodopa/Carbidopa/Entacapone Orion'i rohkem kui ette nähtud
175 mg/43.75 mg/200 mg Each tablet contains 175 mg of levodopa, 43.75 mg of carbidopa and 200 mg of entacapone.
175 mg/43,75 mg/200 mg Iga tablett sisaldab 175 mg levodopat, 43,75 mg karbidopat ja 200 mg entakapooni.
If you stop taking Levodopa/Carbidopa/Entacapone Orion
Kui te lõpetate Levodopa/Carbidopa/Entacapone Orion'i võtmise
If you forget to take Levodopa/Carbidopa/Entacapone Orion
Kui te unustate Levodopa/Carbidopa/Entacapone Orion'i võtta
maprotiline, venlafaxine and paroxetine, - rimiterole and isoprenaline, used to treat respiratory diseases - adrenaline, used for severe allergic reactions - noradrenaline, dopamine and dobutamine, used to treat heart diseases and low blood pressure - alpha-methyldopa, used to treat high blood pressure - apomorphine, which is used to treat Parkinson's disease.
Siia hulka kuuluvad: - depressiooniravimid nagu moklobemiid, amitriptüliin, desipramiin, maprotiliin, venlafaksiin ja paroksetiin - rimiterool ja isoprenaliin, mida kasutatakse hingamisteede haiguste raviks - adrenaliin, mida kasutatakse raskete allergiliste reaktsioonide puhul - noradrenaliin, dopamiin ja dobutamiin, mida kasutatakse südamehaiguste ja madala vererõhu raviks - alfa-metüüldopa, mida kasutatakse kõrge vererõhu raviks - apomorfiin, mida kasutatakse Parkinsoni tõve raviks.
- The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose, titanium dioxide (E171), and yellow iron oxide (E172).
- Koostisosad tableti kattes on glütserool (85 protsenti) (E422), hüpromelloos, magneesiumstearaat, polüsorbaat 80, punane raudoksiid (E172), sahharoos, titaandioksiid (E171) ja kollane raudoksiid (E172).
Brownish or greyish red, elongated-ellipse shaped, unscored film-coated tablets marked with ‘LCE 150' on one side.
Pruunikas-või hallikaspunase värvusega, pikendatud ellipsi kujuline, poolitusjooneta õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 150”.
- The ingredients in the film-coating are glycerol (85 per cent) (E422), hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E172), sucrose and titanium dioxide (E171).
- Koostisosad tableti kattes on glütserool (85 protsenti) (E422), hüpromelloos, magneesiumstearaat, polüsorbaat 80, punane raudoksiid (E172), sahharoos ja titaandioksiid (E171).
150 mg/37.5 mg/200 mg Each tablet contains 150 mg of levodopa, 37.5 mg of carbidopa and 200 mg of entacapone.
150 mg/37,5 mg/200 mg Iga tablett sisaldab 150 mg levodopat, 37,5 mg karbidopat ja 200 mg entakapooni.
Urinary tract infection
Kuseteede infektsioon
levodopa/carbidopa/entacapone orion 75/18.75/200 mg [carton only]
levodopa/carbidopa/entacapone orion 75/18,75/200 mg [ainult karp]
- Each Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg tablet contains 75 mg of levodopa, 18.75 mg of carbidopa and 200 mg of entacapone.
- Iga Levodopa/Carbidopa/Entacapone Orion'i 75 mg/18,75 mg/200 mg tablett sisaldab 75 mg levodopat, 18,75 mg karbidopat ja 200 mg entakapooni.
Excipient with known effect: Each tablet contains 2.3 mg of sucrose.
Teadaolevat toimet omavad abiained: Iga tablett sisaldab 2,3 mg sahharoosi.
When considered necessary, the replacement of Levodopa/Carbidopa/Entacapone Orion with levodopa and DDC inhibitor without entacapone or other dopaminergic treatment should proceed slowly and an increase in levodopa dose may be necessary.
Seega peaks ravimi määrajad olema alati ettevaatlikud, kui asendavad Levodopa/Carbidopa/Entacapone Orion'i levodopa/DDC inhibiitoriga ilma entakapooni või muud dopamiinergilise toimega ravimit lisamata.
Yellow iron oxide (E172)
Titaandioksiid (E171) Kollane raudoksiid (E172)
Thus, a control of INR is recommended when Levodopa/Carbidopa/Entacapone Orion is initiated for patients receiving warfarin.
Seetõttu on INRi väärtuste kontroll näidustatud patsientide puhul, kes saavad lisaks Levodopa/Carbidopa/Entacapone Orion'ile ka varfariinravi.
50 mg/12.5 mg/200 mg Each tablet contains 50 mg of levodopa, 12.5 mg of carbidopa and 200 mg of entacapone.
50 mg/12,5 mg/200 mg Iga tablett sisaldab 50 mg levodopat, 12,5 mg karbidopat ja 200 mg entakapooni.
Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg: light brownish red, oval film-coated tablets marked with ‘LCE 75' on one side.
Levodopa/Carbidopa/Entacapone Orion 75 mg/18,75 mg/200 mg: hele pruunikaspunane, ovaalne õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 75”.
100 mg/25 mg/200 mg Each tablet contains 100 mg of levodopa, 25 mg of carbidopa and 200 mg of entacapone.
100 mg/25 mg/200 mg Iga tablett sisaldab 100 mg levodopat, 25 mg karbidopat ja 200 mg entakapooni.
levodopa/carbidopa/entacapone orion 175/43.75/200 mg [carton only]
Levodopa/Carbidopa/Entacapone Orion 175/43,75/200 mg [ainult karp]
- Each Levodopa/Carbidopa/Entacapone Orion 175 mg/43.75 mg/200 mg tablet contains 175 mg of levodopa, 43.75 mg of carbidopa and 200 mg of entacapone.
- Iga Levodopa/Carbidopa/Entacapone Orion'i 175 mg/43,75 mg/200 mg tablett sisaldab 175 mg levodopat, 43,75 mg karbidopat ja 200 mg entakapooni.
Therefore, caution should be exercised when driving or using machines.
Sel juhul ei tohi te juhtida autot ega teisi masinaid.
levodopa/carbidopa/entacapone orion 125/31.25/200 mg [carton only]
levodopa/carbidopa/entacapone orion 125/31,25/200 mg [ainult karp]
Levodopa/Carbidopa/Entacapone Orion 125 mg/31.25 mg/200 mg: light brownish red, oval filmcoated tablets marked with ‘LCE 125' on one side.
Levodopa/Carbidopa/Entacapone Orion 125 mg/31,25 mg/200 mg: hele pruunikaspunane, ovaalne õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 125”.
Levodopa/Carbidopa/Entacapone Orion contains sucrose
Levodopa/Carbidopa/Entacapone Orion sisaldab sahharoosi
How to transfer patients taking levodopa/DDC inhibitor (carbidopa or benserazide) preparations and entacapone tablets to Levodopa/Carbidopa/Entacapone Orion a. Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Levodopa/Carbidopa/Entacapone Orion tablet strengths can be directly transferred to corresponding Levodopa/Carbidopa/Entacapone Orion tablets.
a. Patsiendid, keda parajasti ravitakse entakapooni ja standardselt vabaneva levodopa/karbidopa preparaadiga annustes, mis on võrdsed Levodopa/Carbidopa/Entacapone Orion'i tableti toimeainete sisaldusega, võib kohe üle viia ravile Levodopa/Carbidopa/Entacapone Orion'iga.
- Each Levodopa/Carbidopa/Entacapone Orion 150 mg/37.5 mg/200 mg tablet contains 150 mg of levodopa, 37.5 mg of carbidopa and 200 mg of entacapone.
- Iga Levodopa/Carbidopa/Entacapone Orion'i 150 mg/37,5 mg/200 mg tablett sisaldab 150 mg levodopat, 37,5 mg karbidopat ja 200 mg entakapooni.
- Each Levodopa/Carbidopa/Entacapone Orion 100 mg/25 mg/200 mg tablet contains 100 mg of levodopa, 25 mg of carbidopa and 200 mg of entacapone.
- Iga Levodopa/Carbidopa/Entacapone Orion'i 100 mg/25 mg/200 mg tablett sisaldab 100 mg levodopat, 25 mg karbidopat ja 200 mg entakapooni.
Each film-coated tablet contains 75 mg of levodopa, 18.75 mg of carbidopa and 200 mg of entacapone.
Iga õhukese polümeerikattega tablett sisaldab 75 mg levodopat, 18,75 mg karbidopat ja 200 mg entakapooni.
Each film-coated tablet contains 175 mg of levodopa, 43.75 mg of carbidopa and 200 mg of entacapone.
Iga õhukese polümeerikattega tablett sisaldab 175 mg levodopat, 43,75 mg karbidopat ja 200 mg entakapooni.
- Each Levodopa/Carbidopa/Entacapone Orion 125 mg/31.25 mg/200 mg tablet contains 125 mg of levodopa, 31.25 mg of carbidopa and 200 mg of entacapone.
- Iga Levodopa/Carbidopa/Entacapone Orion'i 125 mg/31,25 mg/200 mg tablett sisaldab 125 mg levodopat, 31,25 mg karbidopat ja 200 mg entakapooni.
200 mg/50 mg/200 mg Each tablet contains 200 mg of levodopa, 50 mg of carbidopa and 200 mg of entacapone.
200 mg/50 mg/200 mg Iga tablett sisaldab 200 mg levodopat, 50 mg karbidopat ja 200 mg entakapooni.
Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets).
Levodopa/Carbidopa/Entacapone Orion 75 mg/18,75 mg/200 mg tabletid on saadaval viies erinevas pakendi suuruses (10, 30, 100, 130 või 175 tabletti).
Excipient with known effect: Each tablet contains 1.9 mg of sucrose.
Teadaolevat toimet omavad abiained: Iga tablett sisaldab 1,9 mg sahharoosi.
Levodopa/Carbidopa/Entacapone Orion 150 mg/37.5 mg/200 mg: brownish or greyish red, elongatedellipse shaped, unscored film-coated tablets marked with ‘LCE 150' on one side.
Levodopa/Carbidopa/Entacapone Orion 150 mg/37,5 mg/200 mg: pruunikas-või hallikaspunane, pikendatud ellipsi kujuline, poolitusjooneta õhukese polümeerikattega tablett, mille ühele küljele on pressitud märge “LCE 150”.
Other forms of interactions: Since levodopa competes with certain amino acids, the absorption of Levodopa/Carbidopa/Entacapone Orion may be impaired in some patients on high protein diet.
Levodopa/Carbidopa/Entacapone Orion'i imendumine olla vähenenud mõnedel kõrge proteiinisisaldusega dieedil olevatel patsientidel.
Levodopa/Carbidopa/Entacapone Orion 125 mg/31.25 mg/200 mg tablet comes in five different pack sizes (10, 30, 100, 130 or 175 tablets).
Levodopa/Carbidopa/Entacapone Orion 125 mg/31,25 mg/200 mg tabletid on saadaval viies erinevas pakendisuuruses (10, 30, 100, 130 või 175 tabletti).